# A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

> **NCT02951598** · — · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1400 (estimated)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment

## Interventions

- **DRUG:** Florbetapir F 18 PET Scan

## Key facts

- **NCT ID:** NCT02951598
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-29
- **Primary completion:** 2021-01-30
- **Final completion:** 2026-04-28
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951598, "A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02951598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*